ENDRA Life Sciences Announces That Its Ongoing Multisite Pilot Study Has Helped To Identify Several Product Enhancements To Further Improve The Performance Of Its TAEUS Liver System Against The Gold Standard, MRI

Refinements to probe configuration and proprietary algorithms are expected to drive substantial improvements in MRI-PDFF correlation

ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer in imaging technologies for the early detection and monitoring of metabolic liver disease, today announced that its ongoing multisite pilot study has helped to identify several product enhancements to further improve the performance of its TAEUS® Liver system against the gold standard, MRI. These findings are expected to drive substantial improvements to the device's probe design and proprietary algorithms, measurably improving diagnostic accuracy and repeatability. These enhancements are currently being implemented and are expected to strengthen the outcomes of the Company's planned U.S. Food and Drug Administration ("FDA") De Novo pivotal study.

Consistent with its revamped go-to-market strategy, ENDRA is conducting a multisite clinical initiative designed to bolster the diagnostic performance of TAEUS Liver prior to initiation of the FDA pivotal study. In collaboration with several leading imaging centers, the Company has collected liver fat measurement data from more than 100 subjects that compare TAEUS scans against MRI-PDFF.